On August 19, 2026, Moderna and Merck unveiled promising outcomes from the Phase III INTerpath-001 clinical trial of their jointly developed personalized mRNA tumor vaccine, intismeran autogene, administered in conjunction with pembrolizumab (Keytruda). The trial encompassed 1,137 patients afflicted with high-risk melanoma who had previously undergone surgical excision. The combined treatment regimen notably enhanced recurrence-free survival (RFS) and distant metastasis-free survival (DMFS), showcasing both statistical and clinical relevance. This milestone represents the inaugural triumph of a personalized mRNA tumor vaccine in a Phase III clinical trial globally, effectively broadening the application of mRNA technology from infectious disease vaccines to the realm of oncology.

Previous five-year follow-up data from the Phase IIb trial had already indicated that the combined therapy diminished the risk of recurrence or mortality by 49%, and the risk of distant metastasis or mortality by 59%. In light of these results, Moderna and Merck intend to submit regulatory applications for approval and proceed with clinical trials targeting additional tumor types, encompassing non-small cell lung cancer and bladder cancer.